TrialThe Lancet. Oncology2012

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

Nancy Y Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.